Ann: Investor Presentation - $66m Capital Raise, page-75

Thanks, just interested in people's viewpoints.

I see Baker Young have a penetration rate of about 1-1.4% in the first year. They estimate 10% penetration around 2035.

Ultimately these are just forecasts. If we have a DMOAD label then pentration could be very quick. As Marco says it will be 3-4x current forecasts in terms of revenue i.e. $30-$40 bn. You can now see why they are going to take phase 3 as far as possible before signing a deal.

Question for Mozz - in Scott's chat with Paul they mention a synovial fluid study in animals already showing DMOAD. Have you written about this or seen this study? Any info appreciated thanks.